Egypt Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

Egypt Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis


$ 3999

Egypt's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $51 Mn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $99 Mn in 2030. One of the main reasons propelling the growth of this market is government initiatives, Aging population. The market is segmented by drug class and distribution channel. Some key players in this market are EIPICO, Pharco, Amoun, Memphis Pharmaceutical, Eva Pharma, Almirall, Astellas Pharma, American Hospital of Paris, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, and others.

ID: IN10EGPH307 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Nandini Shah

Buy Now

Egypt Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary

The Egypt Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $51 Mn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $99 Mn in 2030. In both industrialized and developing nations, chronic obstructive pulmonary disease (COPD) is regarded as a major source of morbidity and mortality and is a frequent community issue. By 2020, COPD is anticipated to rank as the third-leading cause of death.

The prevalence of COPD (Chronic Obstructive Pulmonary Disease) in Egypt is relatively high, with estimates suggesting that the disease affects approximately 7.5% of the population. The prevalence of COPD is higher among men than women, and it increases with age. Several factors contribute to the high prevalence of COPD in Egypt, including smoking, air pollution, and occupational exposure. Smoking is the most significant risk factor for COPD in Egypt, with approximately 25% of the population being smokers. Air pollution, particularly indoor air pollution from the use of solid fuels for cooking and heating, is also a significant risk factor for COPD in Egypt. Exposure to occupational dust and chemicals is another contributing factor, particularly in industries such as mining, construction, and agriculture.

Egypt COPD therapeutics market analysis report 2022 to 2030

Market Dynamics

Market Growth Drivers

COPD is a significant health problem in Egypt, with a high prevalence rate. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the prevalence of COPD in Egypt was found to be 12.2% in adults aged 40 years and older. This high prevalence of COPD is expected to drive demand for therapeutics in the market. Egypt has a growing geriatric population, and aging is a major risk factor for COPD. According to the World Bank, the percentage of the population aged 65 years and older in Egypt was 5.1% in 2020 and is projected to reach 7.2% by 2030. This demographic trend is expected to drive demand for COPD therapeutics. Smoking is a major risk factor for COPD, and smoking rates in Egypt are among the highest in the world.

According to the World Health Organization, 23.5% of adults in Egypt were smokers in 2019. This high smoking rate is expected to drive demand for COPD therapeutics. The COPD therapeutics market in Egypt is witnessing advancements in drug and device development, which are expected to drive market growth. For instance, new inhalers and nebulizers are being developed that are more effective and user-friendly than traditional devices. The Egyptian government is taking initiatives to improve healthcare infrastructure and services, which is expected to increase access to COPD therapeutics. The government has implemented several programs to improve primary healthcare services, including the provision of free COPD medications to patients.

Market Restraints

There is a lack of awareness among the general population about the causes, symptoms, and treatment options for COPD. This results in a delay in diagnosis and treatment, which can lead to further complications and exacerbations of the disease. The cost of COPD medications and devices can be a significant barrier to access for many patients, particularly those from lower-income households. The cost of treatment may deter some patients from seeking treatment or following through with prescribed treatment plans. Some COPD medications and devices may not be widely available in all parts of Egypt, particularly in rural areas. This can limit access to effective treatments for some patients. The COPD therapeutics market in Egypt is highly competitive, with many international and domestic players vying for market share. This competition can lead to pricing pressures and reduced profit margins for some companies. Despite the government's efforts to improve healthcare infrastructure, there are still significant gaps in healthcare services in Egypt, particularly in rural areas. This can limit access to COPD treatment and diagnosis, particularly for patients living in remote areas.

Competitive Landscape

Key Players

  • EIPICO
  • Pharco
  • Amoun
  • Memphis Pharmaceutical
  • Eva Pharma
  • Abbott Laboratories
  • Adamis Pharmaceuticals Corporation
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim Pharmaceuticals
  • Novartis
  • Pfizer

Healthcare Policies and Regulatory Landscape

The healthcare policy and regulatory framework in Egypt is governed by the Ministry of Health and Population (MoHP). The MoHP is responsible for formulating and implementing healthcare policies, regulations, and guidelines for the country. The regulatory framework for the pharmaceutical industry is overseen by the Egyptian Drug Authority (EDA), which is responsible for approving and regulating drugs and medical devices. The EDA is also responsible for enforcing regulations related to the manufacturing, import, and distribution of pharmaceutical products in Egypt.

In terms of healthcare policy, the Egyptian government has taken several initiatives to improve healthcare services and access to medication for its citizens. The government has implemented several programs to improve primary healthcare services, including the provision of free medications for certain chronic diseases, including COPD. In addition, the Egyptian government has taken steps to improve the affordability of medication. The government has implemented price control measures for essential medications, which include several COPD medications. This has helped to make these medications more affordable for patients.

Reimbursement Scenario

In Egypt, the government provides some form of reimbursement for certain medications and treatments for patients with COPD. The government has implemented several programs to improve access to essential medications, including those used to treat COPD. The government provides free medications for certain chronic diseases, including COPD. Under the national health insurance system, eligible patients can receive free medications and treatments for their condition. However, not all medications used to treat COPD are covered under this program.

Private health insurance companies also provide some form of reimbursement for COPD medications and treatments. However, the extent of coverage and reimbursement rates may vary depending on the specific insurance plan.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Segmentation

By Drug Class

  • Bronchodilators: Bronchodilators are medications that help to relax the muscles around the airways, making it easier to breathe. These can be further classified as short-acting or long-acting bronchodilators
  • Corticosteroids: Corticosteroids are anti-inflammatory medications that can help reduce swelling and inflammation in the airways. These can be used alone or in combination with bronchodilators
  • Combination therapies: Combination therapies combine bronchodilators and corticosteroids in a single medication. These are often used for patients with more severe COPD
  • Phosphodiesterase-4 inhibitors: Phosphodiesterase-4 inhibitors are medications that help to reduce inflammation and improve airflow in the lungs
  • Others: Other medications that may be used to treat COPD include mucolytics, oxygen therapy, and vaccines for influenza and pneumococcal disease

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 07 August 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up